Janux Therapeutics Inc

NASDAQ:JANXUnited States

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Contact Information

Headquarters

10955 Vista Sorrento Parkway, Suite 200SAN DIEGO, CA, United States 92130

Phone

858-751-4493

Fax

302-655-5049

Executives

Chairman of the Board

Jay Lichter

President, Chief Executive Officer, Founder, Director

David Campbell

Acting Chief Financial Officer

Tighe Reardon

Chief Technology Officer

Charles Winter

Chief Business Officer

Andy Meyer